BioSpace News Archive

Anthos Therapeutics presented details of the development of a novel patient-reported outcome assessment scale to measure the patient relevant burden of oral anticoagulant treatment at ISPOR—The Professional Society for Health Economics and Outcomes Research’s annual meeting, held in Boston, May 7-10, 2023.

Hemogenyx Pharmaceuticals plc announces the submission of an Investigational New Drug (“IND”) application seeking authorization from the U.S. Food and Drug Administration (“FDA”) to begin a Phase I clinical trial of its lead product candidate Chimeric Antigen Receptor (“CAR”) T-cells (“HEMO-CAR-T”) for treating acute myeloid leukemia (AML).

Kiora Pharmaceuticals (NASDAQ: KPRX) announced its first quarter 2023 results, during which time it significantly advanced its ocular drug development pipeline of clinical-stage candidates for the treatment of Retinitis Pigmentosa (RP), Persistent Corneal Epithelial Defects (PCEDs), and the Ocular Presentation of Rheumatoid Arthritis (OPRA).

Oxford Biomedica Solutions LLC, offers The Full Solution™ services, which includes end-to-end development and manufacturing capabilities.

Emboline, Inc. today announced the first patient has been treated in the Protect the Head to Head investigational device exemption (IDE) clinical trial (NCT05684146) at New York-Presbyterian Hospital/Columbia University Medical Center in New York, NY.

SYNAPS Dx, a privately held company focused on the research, development and commercialization of a diagnostic test for Alzheimer’s disease, is pleased to announce the release of its white paper, “Resolving a Diagnostic Dilemma.”

CytoMed Therapeutics Limited (Nasdaq: GDTC) (“CytoMed” or the “Company”) today announced it has entered into a research collaboration agreement with The University of Texas MD Anderson Cancer Center (“MD Anderson”) in Houston, Texas.

Guardant Health, Inc. (Nasdaq: GH) today presented additional data from the ECLIPSE study at 2023 Digestive Disease Week (DDW) titled, “Clinical Validation of a Cell-Free DNA Blood-Based Test for Colorectal Cancer in an Average Risk Population” (Abstract #913e) showcasing the performance of its blood-based technology to accurately detect early-stage colorectal cancer (CRC).

The Insight Partners published latest research report on “Molecular Diagnostics Market Growth Report, Size, Share, Trends and Demand Forecast to 2028 - COVID-19 Impact and Global Analysis By Disease Area; Technology; Product and Services; End User and Geography”

SARC is proud to announce that it has launched a national, virtual multidisciplinary sarcoma tumor board.